(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

M MELTECH

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

M MELTECH

ST13

US500000087646531

Class

5

Filing

87646531

Registration

5672365

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

29

Latest update

02/01/2025

Trademark type

Combined

Nice classes

5

Filing date

10/16/2017

Registration date

02/12/2019

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/31/2025

Last transaction

02/01/2025

Responsible office

United States Patent and Trademark Office

Status code

702

Official register

Principal Register

Filing basis

Foreign priority

Drawing code

5

Owner type

16

Owner location

Jerusalem, IL

Examiner

PARK, JENNY

Current location

Historical data usage

Mark description

The mark consists of the word "MELTECH" appearing in stylized blue font with a stylized blue "M" appearing to the left of the wording and extending under the letters "MEL".

Holders and representatives

Holders

Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd.

Representatives

Sarah Anne Keefe Womble Bond Dickinson (US) LLP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations in the form of orally disintegrating tablets and orally disintegrating medicaments for the treatment of geneticcardiovascularcentral nervous systemendocrinegastrointestinalhepaticbiliaryimmunologicalallergicpulmonarydermatologicalinfectiousinflammatorymenopausalnutritionalmetabolicdiabetesautoimmunemusculoskeletalconnective tissueneurologicalophthalmologicpsychiatricrespiratoryurogenitalurologicalerectile dysfunctionsexual dysfunctiongynecologyobstetricpediatrichematologiconcologicalfungal and viral diseases and disorders

Publications

History of USPTO decisions and trademark events.

29 publications found

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

01/31/2025

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

01/31/2025

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

01/31/2025

E815

TEAS SECTION 8 & 15 RECEIVED

09/13/2024

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

02/12/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

02/12/2019

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

11/27/2018

PUBO

PUBLISHED FOR OPPOSITION

11/27/2018

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

11/07/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

10/18/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/17/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/17/2018

ALIE

ASSIGNED TO LIE

10/17/2018

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

10/05/2018

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

04/13/2018

GNSL

LETTER OF SUSPENSION E-MAILED

04/13/2018

CNSL

SUSPENSION LETTER WRITTEN

04/13/2018

ZZZX

PREVIOUS ALLOWANCE COUNT WITHDRAWN

04/13/2018

ERRR

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

03/30/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/28/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/15/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

03/14/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

03/14/2018

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

12/27/2017

GNRT

NON-FINAL ACTION E-MAILED

12/27/2017

CNRT

NON-FINAL ACTION WRITTEN

12/27/2017

DOCK

ASSIGNED TO EXAMINER

12/22/2017

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

10/25/2017

NWAP

NEW APPLICATION ENTERED

10/19/2017

Continuous trademark protection

Get notified about every new filing that threatens M MELTECH or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.